Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Swiss start-up Anaveon has raised about $35 million in its series A financing, led by the British life sciences investor Syncona and supported by the Novartis Venture Fund. The biotech is developing antibody agonists of the interleukin-2 receptor, with the goal of boosting the immune system’s ability to attack tumors in combination with other cancer therapies. Anaveon was founded in 2017 by IL-2 expert Onur Boyman, from the University of Zurich, and Andreas Katopodis, a former R&D director at Novartis.
This article has been sent to the following recipient: